InventisBio, a Shangai, China-based clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, closed a $147m series D financing.
Entities controlled by Levo Chan, CEO of Tak Chun Group, are reportedly making a new offer for approx. 29.2% of the shares of Macau Legend Development Ltd. (SEHK Stock Code: 1680), a casino services and hotel company.
Biocytogen, a Chinese clinical stage company, completed its series D1 funding raising USD 142m.
ImmVira Group Company, a Chinese biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, signed US$10m Series B Plus strategic financing.
JD.com Inc, the large Chinese ecommerce retailer, reported very healthy revenue and earnings for the period April – June 2020.
Dreame Technology, a Beijing, China-based smart consumer technology company, raised nearly RMB 100 million (US$14.6m) in its Series B+ funding.
InxMed (Nanjing) Co., Ltd., a Nanjing, China-based clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, completed a Series A+ financing of approx. US$19m.
The Eruditus group, consisting of Eruditus Executive Education and its online division EMERITUS, completed its Series D funding totaling $113m.
Connect Biopharma, a San Diego, CA- and Taicang, China-based clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules, completed $115m Series C financing.
Waterdrop, a Beijing, China-based insurance platform, raised $230m in Series D funding.
Tungee, a Guangzhou, China-based sales intelligence company, completed an RMB 120m (~$17m) Series B financing.
SandStar, a Charlotte, NC and Beijing, China-based AI+Retail tech company, received an investment from True Digital Group (TDG), a digital arm of True Corporation, a Thailand telecommunication company and an affiliate of the Thai conglomerate C.P. Group.
JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, acquired Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.
TikTok, the Chinese video-sharing social networking service, has launched a $200M creator fund.
Antengene Corporation, a Shangai, China-based hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, closed US$97m Series C financing round.